Tradestie Institutional Equity Comparison Engine

PYPD vs ABOS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PYPD Overall Edge

PYPD Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PolyPid Ltd. Ordinary Shares (PYPD) driven by superior Momentum & Technical, Options & Structure while ABOS counters with relative strength in Growth & Margin. Fundamentally, PYPD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ABOS at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, PYPD sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro) against ABOS sits in UNCLASSIFIED (41st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
PYPD N/M vs ABOS N/M Fwd P/E
Growth & Margin Winner ABOS
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner PYPD
1Y +81.0% vs -87.2% ยท 52W Pos 82% vs 1%
Options & Structure Winner PYPD
BREAKOUT (12th %ile IV) vs UNCLASSIFIED (41st %ile IV)
PYPD NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.50
+5.63% 1D
Market Cap $132.2M
1M Return +33.12%
1Y Return +80.95%
Forward P/E N/M
Unified AI Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
ABOS NASDAQ
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.22
+2.08% 1D
Market Cap $15.5M
1M Return -87.54%
1Y Return -87.25%
Forward P/E N/M
Unified AI Score
49.5 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 68.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PYPD +80.95% ABOS -87.25% Spread: +168.2 pp (PYPD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
PYPD TTM Op. Margin: 0.0% ABOS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs ABOS. Trailing 12-month operating profitability (PYPD 0.0% vs ABOS 0.0%) and valuation multiples (PYPD N/M vs ABOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PYPD (3) vs ABOS (2)
Institutional Metric PYPD ABOS Criterion Row Winner
Market Capitalization Scale $132.2M $15.5M Larger Scale PYPD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -243.6% -162.7% Higher ROE ABOS
52-Week Range Position Momentum 82% ($4โ€“$7) 1% ($0โ€“$4) Stronger Trend PYPD
Beta / 30D Volatility Risk Regime 0.88ฮฒ ยท 59% Vol 2.61ฮฒ ยท 327% Vol Lower Realized Risk PYPD
Unified Institutional Score Composite Signal 31.1 / 100 (SELL) 49.5 / 100 (HOLD) Higher Composite ABOS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PYPD vs ABOS Buy Guide
PYPD BREAKOUT
40d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live PYPD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABOS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 41st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABOS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PYPD nor ABOS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.